Deriving from bioengineered Escherichia coli strain, Gujrati et al. modified human epidermal growth factor receptor 2 (HER2)-specific affibody onto the membrane of OMV as a tumor-targeting ligand. The gene discussed is ERBB2; the disease is neoplasm.